LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Inicio・Lista de Acciones・Sana Biotechnology Inc

Sana Biotechnology Inc

Cerrado

SectorSalud

4.33 -6.48

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.33

Máximo

4.6899999999999995

Métricas clave
By Trading Economics
Ingresos	52M -42M
BPA	-0.15
Margen de beneficio	-321.09
Empleados	194
EBITDA	56M -39M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+51.19% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	58M 1.2B
Apertura anterior	10.81
Cierre anterior	4.33

Noticias sobre sentimiento de mercado

By Acuity

50%

182 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

1.68 / 1.87 Soporte y Resistencia

Sana Biotechnology Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 dic 2025, 22:13 UTC

Ganancias

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Ganancias

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

Principales Movimientos del Mercado

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Ganancias

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Charlas de Mercado

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Charlas de Mercado

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Charlas de Mercado

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Ganancias

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Ganancias

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Ganancias

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Comparación entre iguales

Cambio de precio

Sana Biotechnology Inc Esperado

Precio Objetivo

By TipRanks

51.19% repunte

Estimación a 12 meses

Media 7 USD 51.19%

Máximo 9 USD

Mínimo 5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sana Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Sana Biotechnology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.68 / 1.87Soporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Sentimiento

By Acuity

182 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.